Burns - Pipeline Review, H2 2016

Date: August 31, 2016
Pages: 106
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BE99E0EA53AEN
Leaflet:

Download PDF Leaflet

Burns - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Burns - Pipeline Review, H2 2016’, provides an overview of the Burns pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Burns, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burns and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Burns
  • The report reviews pipeline therapeutics for Burns by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Burns therapeutics and enlists all their major and minor projects
  • The report assesses Burns therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Burns
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Burns
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Burns pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Burns Overview
Therapeutics Development
Pipeline Products for Burns - Overview
Pipeline Products for Burns - Comparative Analysis
Burns - Therapeutics under Development by Companies
Burns - Therapeutics under Investigation by Universities/Institutes
Burns - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Burns - Products under Development by Companies
Burns - Products under Investigation by Universities/Institutes
Burns - Companies Involved in Therapeutics Development
Adocia
AlgiPharma AS
Amarantus Bioscience Holdings, Inc.
American Gene Technologies International Inc.
Biogenomics Limited
CytoTools AG
Destiny Pharma Limited
Lakewood-Amedex Inc
Madam Therapeutics B.V.
MediWound Ltd.
Mitochon Pharmaceuticals, Inc.
Phosphagenics Limited
Se-cure Pharmaceuticals Ltd.
Sinclair Pharma Plc
Stratatech Corporation
Tissue Therapies Limited
USV Pvt Ltd
Burns - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
A-3APO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AG-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
albumin (recombinant) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALLO-ASC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biochaperone PDGF-BB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics for Multi Drug Resistant Bacterial Infections, Dermatology and Cystic Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bromelains - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Congenital Giant Hairy Nevus and Severe Burns - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Dermatology and Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epidermal growth factor biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Burns - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMSP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody Conjugate to Target TNF-alpha for Burns, Inflammation and Wounds - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Neu-2000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nu-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligomer G for Wounds And Burns - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEP-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
silver sulfadiazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Burn - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sodium hypochlorite - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VF-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XF-70 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Burns - Dormant Projects
Burns - Discontinued Products
Burns - Product Development Milestones
Featured News & Press Releases
Jun 07, 2016: MediWound’s NexoBrid Receives Reimbursement in Italy
May 19, 2016: MediWound’s NexoBrid Highlighted in “Best Oral Presentation” at the British Burn Association 49th Annual Conference and Scientific Meeting
May 02, 2016: MediWound’s NexoBrid to be Highlighted in Presentations at the American Burn Association 48th Annual Meeting
Feb 29, 2016: MediWound Expands NexoBrid to India, Bangladesh and Sri Lanka Through Distribution Agreement With Learning Organized
Feb 03, 2016: Amarantus Receives Dual Notices of Allowance from European Patent Office for Engineered Skin Substitute (ESS)
Jan 11, 2016: MediWound's NexoBrid Highlighted in Presentations at the 4th International Conference on Healthcare System Preparedness and Response to Emergencies and Disasters
Nov 02, 2015: MediWound Provides Humanitarian Aid for a Mass Casualty Event in Romania
Oct 20, 2015: Argentina's Ministry of Health Approves MediWound's NexoBrid
Sep 30, 2015: MediWound Awarded BARDA Contract Valued Up to $112 Million for Development and Procurement of NexoBrid for the U.S.
Sep 29, 2015: MediWound Reports Highlights From the European Burns Association Congress
Sep 10, 2015: MediWound's NexoBrid Highlighted at the 16th European Burns Association Congress
Apr 29, 2015: Poster Presentation Highlighting NexoBrid Awarded Best-in-Category in Wound Care Practice at the American Burn Association 47th Annual Meeting
Apr 21, 2015: MediWound's NexoBrid Highlighted in Presentations at the 2015 American Burn Association 47th Annual Meeting
Apr 20, 2015: MediWound Initiates U.S. Phase 3 Trial With NexoBrid to Treat Severe Burns
Mar 23, 2015: MediWound's NexoBrid Highlighted in a Presentation at the International Conference on Minimally Invasive Medicine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Burns, H2 2016
Number of Products under Development for Burns - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Investigation by Universities/Institutes, H2 2016
Burns - Pipeline by Adocia, H2 2016
Burns - Pipeline by AlgiPharma AS, H2 2016
Burns - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
Burns - Pipeline by American Gene Technologies International Inc., H2 2016
Burns - Pipeline by Biogenomics Limited, H2 2016
Burns - Pipeline by CytoTools AG, H2 2016
Burns - Pipeline by Destiny Pharma Limited, H2 2016
Burns - Pipeline by Lakewood-Amedex Inc, H2 2016
Burns - Pipeline by Madam Therapeutics B.V., H2 2016
Burns - Pipeline by MediWound Ltd., H2 2016
Burns - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016
Burns - Pipeline by Phosphagenics Limited, H2 2016
Burns - Pipeline by Se-cure Pharmaceuticals Ltd., H2 2016
Burns - Pipeline by Sinclair Pharma Plc, H2 2016
Burns - Pipeline by Stratatech Corporation, H2 2016
Burns - Pipeline by Tissue Therapies Limited, H2 2016
Burns - Pipeline by USV Pvt Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Burns - Dormant Projects, H2 2016
Burns - Dormant Projects (Contd.1), H2 2016
Burns - Dormant Projects (Contd.2), H2 2016
Burns - Discontinued Products, H2 2016

LIST OF FIGURES

Number of Products under Development for Burns, H2 2016
Number of Products under Development for Burns - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

COMPANIES MENTIONED

Adocia
AlgiPharma AS
Amarantus Bioscience Holdings, Inc.
American Gene Technologies International Inc.
Biogenomics Limited
CytoTools AG
Destiny Pharma Limited
Lakewood-Amedex Inc
Madam Therapeutics B.V.
MediWound Ltd.
Mitochon Pharmaceuticals, Inc.
Phosphagenics Limited
Se-cure Pharmaceuticals Ltd.
Sinclair Pharma Plc
Stratatech Corporation
Tissue Therapies Limited
USV Pvt Ltd
Skip to top


NeurAxon, Inc. - Product Pipeline Review - 2014 US$ 1,125.00 Sep, 2014 · 23 pages

Ask Your Question

Burns - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: